CagriSema (investigational)
cagrilintide + semaglutide · Amylin analog + GLP-1 receptor agonist combination · Novo Nordisk
In short
CagriSema (cagrilintide + semaglutide) is an investigational amylin analog + GLP-1 receptor agonist combination from Novo Nordisk. It is not approved and cannot legally be bought outside a registered clinical trial. Not FDA-approved. Filed December 18, 2025; Novo Nordisk guides to an FDA decision in Q4 2026.
What it is used for
- Under FDA review for chronic weight management
CagriSema dosage
Per the official label. Your prescriber sets your dose — never change it on your own.
| 1Status | No approved dosing — investigational |
|---|
How to take it
Not available outside clinical trials.
Storage
—
How it works
Safety
Safety data come from clinical trials only. Gastrointestinal effects were the most common, as with other incretin medicines.
Cost
No price until approval.
Can you buy CagriSema?
No. It is not approved, so there is no legal way to purchase or order it outside a registered clinical trial. Search ClinicalTrials.gov for trials near you.
Frequently asked questions
How did CagriSema compare with tirzepatide?
In REDEFINE 4 (Feb 2026), CagriSema achieved 23.0% weight loss versus 25.5% with tirzepatide 15 mg and missed its non-inferiority goal.
Can I buy CagriSema online?
No. Anything sold as CagriSema today is unapproved and unverified.
Also searched as: cagrilintide, cagrilintide semaglutide, CagriSema approval, CagriSema release date, Cagri Sema
Sources
Checked against these primary sources on .